References
1. IDF Diabetes Atlas. 8th ed. Brussels: International Diabetes Federation, 2017. https://www.idf.org/e-library/epidemiologyresearch/diabetesatlas/134-idf-diabetes-atlas8th-edition.html
2. Carls G., Huynh J., Tuttle E. et al. Achivement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017; 8 (4): 863-73.
URL: https://www.ncbi.nlm.nih.gov/pubmed/28646411
DOI: 10.1007/s13300-017-0280-5
3. Khunti K., et al. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis.
URL: https://www.ncbi.nlm.nih.gov/pubmed/29325774
DOI: 10.1016/j.diabres.2017.12.004
4. Hu F.B., Stampfer M.J., Haffiier S.M., Solomon C.G., et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002; 7: 1129-34.
5. Reaven G.M. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism. 1992; 41 (suppl. 1): 16-9.
6. Hsueh W.A., Law R.E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med. 1998; 105 (1A): 4-14.
7. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44 (2): 14-21.
8. Budoff M.J. Not all diabetics are created equal (in cardiovascular risk). Eur Heart J. 2008; 29 (18): 2193-4.
9. Haffner S.M., Lehto S., Ronnemaa T. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. N Engl J Med. 1998; 339: 229-34.
URL: https://www.ncbi.nlm.nih.gov/pubmed/9673301
DOI: 10.1056/NEJM199807233390404
10. Dedov I.I., Shestakova, M.V., Majorov A.A., eds. Specialized medical diabetes. 8th edition. Moscow: UP PRINT; 2017. 112 p. (in Russian)
URL: dia-endojournals.ru/dia/article/view/8341
DOI: 10.14341/DM20171S8
11. Dedov I.I., Shestakova M.V., Mayorov A.Yu., eds. Standards of specialized diabetes care. 9th edition. Diabetes. Moscow: UP PRINT; 2019. (in Russian)
URL: https://dia-endojournals.ru/dia/article/view/12211
DOI: 10.14341/DM221S1
12. Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019. pii: ehz486.
URL: https://academic.oup.com/eurheartj/article/41/2/255/5556890
DOI: 10.1093/eurheartj/ehz486
13. Khunti K., Wolden M.L., Thorsted B.L., et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013; 36 (11): 3411-7.
14. Paul S.K., Klein K., Thorsted B.L., et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015; 14: 100.
URL: https://cardiab.biomedcentral.com/articles/10.1186/s12933-015-0260-x
DOI: 10.1186/s12933-015-0260-x
15. Mathews D.R., et al. VERIFY (Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes). Diabetes Obes Metab. 2019; 21 (10): 2240-7.
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771473/
DOI: 10.1111/dom.13800
16. Turner R.C., et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). JAMA 1999; 281 (21): 2005-12.
17. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-53.
18. Zhang X., Wang Y., Huang J., et al. Effects of chronic administration of alogliptin on the development of diabetes and p-cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab. 2011; 13 (4): 337-47.
URL: https://www.ncbi.nlm.nih.gov/pubmed/21205126
DOI: 10.1111/j.1463-1326.2010.01354.x
19. Jurczyk A., Diiorio P., Brostowin D., et al. Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2ry(null) mice treated with alogliptin. Diabetes Metab Syndr. Obes. 2013; 6: 493-9.
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864939/
DOI: 10.2147/DMSO.S53154
20. DeFronzo R., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care. 2008; 31 (12): 2315-7.
21. Liu Y., Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab. 2014; 16 (2): 111-7
URL: https://onlinelibrary.wiley.com/doi/full/10.1111/dom.12128
DOI: 10.1111/dom.12128
22. Wu D., Li L., Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014; 16 (1): 30-7.
URL: https://onlinelibrary.wiley.com/doi/full/10.1111/dom.12174
DOI: 10.1111/dom.12174
23. Bianchi C., Daniele G., Dardano A., Miccoli R., et al. Early combination therapy with oral glucose-lowering agents in type 2 diabetes. Drugs. 2017; 77 (3): 247-64.
24. Schwartz S.S., Epstein S., Corkey B.E., et al The time is right for a new classification system for diabetes: rationale and implications of the p-cell-centric classification schema. Diabetes Care. 2016; 39 (2): 179-186.
URL: https://care.diabetesjournals.org/content/39/2/179
DOI: 10.2337/dc15-1585
25. Davies M.J., D’Alessio D.A., Fradkin J., Kerman W.N., et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41 (12): 2669-701.
URL: https://care.diabetesjournals.org/content/41/12/2669
DOI: 10.2337/dci18-0033
26. Capuano A., Giugliano, D., Sportiello L., et al. Dipeptidyl peptidase-4 inhibitors in ype 2 diabetes therapy - focus on alogliptin. Drug Des Dev Ther. 2013; 7: 989-1001.
URL: https://www.ncbi.nlm.nih.gov/pubmed/24068868
DOI: 10.2147/DDDT.S37647
27. Nauck M.A, Ellis G.C, Fleck P.R, Wilson C.A., et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009; 63: 46-55.
28. Bosi E., Ellis G.C., Wilson C.A., Fleck P.R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, doubleblind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011; 13: 1088-96.
29. Rosenstock J., Rendell M.S., Gross J.L., Fleck P.R., et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009; 11: 1145-52.
30. Zannad F., Cannon C.P., Cushman W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385: 2067-76.
31. Shestakova M.V., Kachko V.A. ENTIRE: a study of real clinical practices of application of alogliptin in therapy of patients with diabetes mellitus type 2 in the Russian Federation. Russkiy meditsinskiy zhurnal [RMJ]. 2019. No. 8 (1). C. 3-10. (in Russian)
32. Wu J.Y., Leung W.Y., Chang S., et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ. 2006; 333: 522.
URL: https://www.bmj.com/content/333/7567/522
DOI: 10.1136/bmj.38905.447118.2F
33. Del Prato S., Camisasca R., Wilson C., Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014; 16: 1239-46.